Lemaitre Vascular (LMAT) closed at $87.92 on November 4, 2026, up 9.1% from the previous close, on volume of 464,128 shares (30-day average 261,239).
Data as of November 4, 2026.
4-Nov-2026
TipRanks (Thu, 5-Nov 6:10 AM ET)
TipRanks (Thu, 5-Nov 3:50 AM ET)
LeMaitre Vascular declares $0.25 dividend
Seeking Alpha News (Wed, 4-Nov 9:30 PM ET)
LeMaitre Vascular GAAP EPS of $0.65 misses by $0.04, revenue of $68M beats by $0.63M
Seeking Alpha News (Wed, 4-Nov 4:34 PM ET)
LeMaitre Q3 2026 Financial Results
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Here are the major earnings after the close Wednesday
Seeking Alpha News (Wed, 4-Nov 10:00 AM ET)
LeMaitre Vascular Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 3-Nov 5:35 PM ET)
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026
Globe Newswire (Mon, 12-Oct 4:49 PM ET)
PRNewswire (Wed, 23-Sep 11:20 PM ET)
LeMaitre to Participate at Upcoming Investor Conferences in September
Globe Newswire (Thu, 27-Aug 4:51 PM ET)
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Lemaitre Vascular trades on the NASDAQ stock market under the symbol LMAT.
As of November 4, 2026, LMAT stock price climbed to $87.92 with 464,128 million shares trading.
LMAT has a beta of -0.30, meaning it tends to be less sensitive to market movements. LMAT has a correlation of 0.01 to the broad based SPY ETF.
LMAT has a market cap of $2.01 billion. This is considered a Mid Cap stock.
Last quarter Lemaitre Vascular reported $70 million in Revenue and $.74 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.07.
In the last 3 years, LMAT traded as high as $118.01 and as low as $47.72.
The top ETF exchange traded funds that LMAT belongs to (by Net Assets): IJR, SDVY, VTI, IWM, VXF.
LMAT has underperformed the market in the last year with a return of +1.8%, while the SPY ETF gained +14.7%. In the last 3 month period, LMAT fell short of the market, returning -16.6%, while SPY returned -0.3%. However, in the most recent 2 weeks LMAT has outperformed the stock market by returning +5.1%, while SPY returned -0.8%.
LMAT support price is $79.03 and resistance is $82.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LMAT shares will trade within this expected range on the day.